Results 211 to 220 of about 7,007,196 (291)

Correction: Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm- a model to enhance the HCV continuum of care. [PDF]

BMC Psychiatry
Klasa PE, Sandell M, Aleman S, Kåberg M.   +3 more
europepmc   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1092-1100, October 2026.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study. [PDF]

PLoS One
Kurz M, Tatangelo M, Morin KA, Zanette M, Krebs E, Marsh DC, Nosyk B.   +6 more
europepmc   +1 more source

Evaluation of a Real‐Time Knowledge Exchange Network Supporting Syphilis Rapid Testing and Immediate Treatment in Seven Public Health Units in Ontario, Canada

Learning Health Systems, Volume 10, Issue 4, October 2026.
ABSTRACT Introduction The Syphilis Point of care Rapid testing and Immediate Treatment Evaluation (SPRITE) is a collaborative, community‐based initiative that strengthens syphilis prevention and control in Ontario, Canada through flexible outreach nursing and point‐of‐care testing (POCT) and immediate treatment.
Megan Ann Carter, Sara Tryon, Mary Southall, Kandace Belanger, Mary France Caron‐Bruneau, Anne Charron, Sandra Dereski, Michael Evans, Natasha Larkin, Kassandra Plante, Melanie St. John, Nicole Szumlanski, Lucy Mackrell, Sahar Saeed   +13 more
wiley   +1 more source

Cohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada. [PDF]

Eur J Epidemiol
Morin KA, Tatangelo MR, Acharya S, Marsh DC.   +3 more
europepmc   +1 more source

Evaluating the Impact of Clonidine and Midazolam Premedication on Emergence Delirium in Pediatric Patients

Pediatric Anesthesia, Volume 36, Issue 10, Page 1290-1307, October 2026.
ABSTRACT Background Preoperative anxiety is common in children and is associated with emergence delirium—a distressing postoperative complication characterized by agitation and disorientation. Midazolam has long been the drug of choice for preoperative anxiolysis.
Anne Louise de Barros Garioud, Anwen Taplin, Yufei Shang, R. Nazim Khan, David Sommerfield, Neil Hauser, Aine Sommerfield, Britta S. von Ungern‐Sternberg   +7 more
wiley   +1 more source

Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada: a cohort study using inverse probability of treatment weights. [PDF]

BMJ Public Health
Ledlie S, Tadrous M, Bayoumi AM, McCormack D, Kent JT, Besharah J, Munro C, Gomes T.   +7 more
europepmc   +1 more source

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

Exploring the early impacts of drug decriminalization on harm reduction and opioid agonist treatment service operations and delivery in British Columbia: insights from key informant interviews. [PDF]

BMC Public Health
Russell C, Torres-Salbach S, MacKinnon L, Shahin R, Griffith D, Hodgson K, Burmeister C, Amoraal C, Crichlow F, Imtiaz S, Rehm J, Ali F.   +11 more
europepmc   +1 more source

Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ‐Opioid Receptor via an Endoplasmic Reticulum Exit Site‐Dependent Pathway

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Opioid receptor antagonists increase the plasma membrane density of μ‐opioid receptors (MOR) in vivo, thereby inducing “supersensitivity” to opioid agonists. This phenomenon increases the risk of overdose in patients that were being treated with naltrexone (Ntx), a popular MOR antagonist.
Stephen N. Grant, Matthew J. Mulcahy, Henry A. Lester   +2 more
wiley   +1 more source